Residency · Syracuse, NY
Sponsored by SUNY Upstate Medical University
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
The Lancet. Oncology · 2021 · 402 citations · Gennady Bratslavsky
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · 42 citations · Joseph Jacob
Robotic-assisted surgery for the treatment of urologic cancers: recent advances.
Expert review of medical devices · 2024 · 37 citations · Osama Zaytoun
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
The Journal of urology · 2024 · 81 citations · Gennady Bratslavsky
Gut microbiota aggravates neutrophil extracellular traps-induced pancreatic injury in hypertriglyceridemic pancreatitis.
Nature communications · 2023 · 91 citations · Guanqun Li
Effects of preconception lifestyle intervention in infertile women with obesity: The FIT-PLESE randomized controlled trial.
PLoS medicine · 2022 · 83 citations ·
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.
The Lancet. Oncology · 2024 · 83 citations · Gennady Bratslavsky
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Nature medicine · 2024 · 59 citations · Joseph Jacob